U.S. Markets open in 8 hrs 32 mins
  • S&P Futures

    3,834.00
    +8.50 (+0.22%)
     
  • Dow Futures

    30,988.00
    +55.00 (+0.18%)
     
  • Nasdaq Futures

    11,714.75
    +40.50 (+0.35%)
     
  • Russell 2000 Futures

    1,742.20
    +3.90 (+0.22%)
     
  • Crude Oil

    111.22
    -0.54 (-0.48%)
     
  • Gold

    1,822.60
    +1.40 (+0.08%)
     
  • Silver

    20.73
    -0.08 (-0.37%)
     
  • EUR/USD

    1.0511
    -0.0014 (-0.1366%)
     
  • 10-Yr Bond

    3.2060
    0.0000 (0.00%)
     
  • Vix

    28.36
    +1.41 (+5.23%)
     
  • GBP/USD

    1.2201
    +0.0016 (+0.1330%)
     
  • USD/JPY

    136.0190
    -0.1090 (-0.0801%)
     
  • BTC-USD

    20,323.87
    -441.63 (-2.13%)
     
  • CMC Crypto 200

    440.65
    -9.41 (-2.09%)
     
  • FTSE 100

    7,323.41
    +65.09 (+0.90%)
     
  • Nikkei 225

    26,767.11
    -282.36 (-1.04%)
     

Pipeline Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

·1 min read

SAN DIEGO, May 26, 2022--(BUSINESS WIRE)--Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that company management will present at the Jefferies Global Healthcare Conference taking place June 8-10, 2022 in New York, NY. Carmine Stengone, Pipeline’s President and CEO, will present a company overview on Thursday, June 9, 2022 at 10:00 am ET. Company management will also participate in one-on-one meetings with investors during the conference.

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address CNS and neuro-otology conditions. Its flagship program, PIPE-307, has completed a Phase 1 clinical trial in healthy volunteers and has received IND clearance from the FDA to initiate a Phase 1b/2a trial in relapsing-remitting MS patients. For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005179/en/

Contacts

Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com